Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $78.08, marking a +0.64% move from the previous day.

Should Value Investors Consider Abbvie (ABBV) Stock Now?

Let's see if Abbvie (ABBV) stock is a good choice for value-oriented investors right now from multiple angles.

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.

Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC

Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.

Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy

The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy

AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab

AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.

Mark Vickery headshot

Top Research Reports for Intel, AbbVie & United Technologies

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), AbbVie (ABBV) and United Technologies (UTX).

Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices

Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.

Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat

Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

AbbVie Extends Deal With Voyager to Make Parkinson's Drugs

AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.

Why Is AbbVie (ABBV) Down 6.8% Since Last Earnings Report?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review

AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.

Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review

The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.

Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance

Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

The Zacks Analyst Blog Highlights: Union Pacific, AbbVie and General Dynamics

The Zacks Analyst Blog Highlights: Union Pacific, AbbVie and General Dynamics

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

Mark Vickery headshot

Top Research Reports for Union Pacific, AbbVie & General Dynamics

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), AbbVie (ABBV) and General Dynamics (GD).